

**Date: October 28, 2023**

**BSE Limited**

P J Towers,  
Dalal Street,  
Mumbai – 400 001

**National Stock Exchange of India Limited**

Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**Script Code: 543904**

**Symbol: MANKIND**

Dear Sir/ Madam,

**Subject: Intimation for receipt of request for reclassification of shareholding from “Promoter and Promoter Group” Category to “Public” Category pursuant to the provisions of Regulation 31A of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”).**

---

Pursuant to the provision of Regulation 31A(8)(a) of the SEBI Listing Regulations, we hereby inform your good office that we are in receipt of request letter dated October 27, 2023, from M/s. EzeRx Health Tech Private Limited, (enclosed herewith as Annexure) requesting reclassification from “Promoter and Promoter Group” Category to “Public” Category in terms of the provisions of Regulation 31A of the SEBI Listing Regulations.

The said request will be placed before the board of directors in their ensuing meeting for their consideration and the Company will take all other necessary approvals in terms of Regulations 31A of the SEBI Listing Regulations.

You are requested to kindly take the above information on your records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

**Pradeep Chugh**  
**Company Secretary and Compliance Officer**  
**Membership No. A18711**

Encl: As above



**EzeRx**<sup>TIA</sup>  
EASY FOR PRESCRIPTION



**REGISTERED OFFICE :**

Kriya, Barana, Egra  
East Midnapore,  
West Bengal, 721428



**CORPORATE OFFICE :**

EzeRx Towers, Plot Nos. CP 52 & 53  
Sector - VI, Madhvi Vihar,  
Bhubaneswar, Odisha - 751021

CIN No. U74999WB2018PTC225255

GST No. 21AAFCE10500125

Date: 27 October, 2023

To  
The Board of Directors  
Mankind Pharma Limited  
208, Okhla Industrial Area, Phase III  
New Delhi – 110020

Dear Sir/Madam

**Subject: Request for re-classification of EzeRx Health Tech Private Limited from the “Promoter & Promoter Group” Category to “Public” Category of Mankind Pharma Limited (“the Company”/ “Mankind”) in accordance with the provisions of Regulation 31A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), 2015 (“SEBI Listing Regulations”).**

With reference to the captioned subject, I, Chaitali Roy (DIN:08221264), director of EzeRx Health Tech Private Limited (“EzeRx”) , do hereby state that EzeRx is being shown as the member of Promoter & Promoter Group in the shareholding pattern of Mankind Pharma Limited(Mankind) as some of the Promoters of Mankind Pharma Limited used to Jointly holds more than 20% of equity share in EzeRx , however, it holds NIL equity shares representing 0.00% of the paid-up equity share capital of the Mankind, does not exercise any control, directly or indirectly over the affairs of the Company and does not have any representation over the Board of Directors or any key managerial personnel/employee of the Company. In light of the same, we are writing this letter to request you to reclassify EzeRx from “Promoter & Promoter Group” Category to “Public” Category in shareholding pattern of the Company pursuant to the provisions of Regulation 31A of SEBI Listing Regulations.



[www.ezerx.in](http://www.ezerx.in)



[support@ezerx.in](mailto:support@ezerx.in)



**EzeRx**<sup>TM</sup>  
EASY FOR PRESCRIPTION



**REGISTERED OFFICE :**

Kiya, Bartana, Egra  
East Midnapore,  
West Bengal, 721429



**CORPORATE OFFICE :**

EzeRx Tower, Plot No: CP 52 & 53  
Sector - IV, Niladri Vihar,  
Bhubaneswar, Odisha - 751021

CIN No. U74999WB2018PTC226850

GST No. 21AAFCE1050Q1ZS

Rationale for request to re-classify

EzeRx do not directly or indirectly, exercise any control over the affairs of the Mankind and hold NIL equity shares representing 0.00% of the paid-up equity share capital of the Mankind. EzeRx do not directly or indirectly participate in the management or policy decisions of the Mankind and EzeRx neither have any representation on the Board of Directors of the Mankind nor any special rights. EzeRx also not involved in the management of affairs of the Mankind in any manner. Pursuant to share purchase agreement dated 10 May 2023 executed among

“Ezerx”, Chaitali Roy(transferee) and abovesaid some of the Promoters of Mankind Pharma Limited (transferor), Promoters of Mankind Pharma Limited transferred all the shares held in Ezerx to transferee. Consequently, Ezerx Ceased to be classified under **“Promoter & Promoter Group”**

In connection with above reclassification request, I, Chaitali Roy (DIN:08221264), Director of EzeRx confirms and undertake the following:

1. That as on the date of this letter, EzeRx do not hold more than ten percent of the total voting rights in the Company.
2. That it does not exercise control over the affairs of the company, directly or indirectly.
3. That it does not have any special rights with respect to the company through formal or informal arrangements including through any shareholder agreements.
4. That none of its representatives are being represented on the board of directors (including not having a nominee director) of the Company.
5. That it do not act as a key managerial person of the Company.
6. That it is neither a ‘wilful defaulter(s)’ as per the Reserve Bank of India Guidelines nor a fugitive economic offender.

EzeRx shall abide by the applicable conditions as mentioned in Regulation 31A(4) of SEBI Listing Regulations post receipt of approval for reclassification of EzeRx from Promoter & Promoter Group Category to Public Category .



[www.ezerx.in](http://www.ezerx.in)



[support@ezerx.in](mailto:support@ezerx.in)



**EzeRx**<sup>TM</sup>  
EASY FOR PRESCRIPTION



**REGISTERED OFFICE :**

Kya, Barana, Egra  
East Midnapore,  
West Bengal, 721429



**CORPORATE OFFICE :**

EzeRx Tower, Plot No: CP 52 & 53  
Sector - IV, Niladri Vihar,  
Bhubaneswar, Odisha - 751021

CIN No. U74999WB2018PTC226850

GST No. 21AAFCE1050Q1ZS

EzeRx is not in violation of the restrictions imposed by SEBI under SEBI circular no. SEBI/HO/ MRD/DSA/CIR/P/2017/92 dated August 01, 2017.

EzeRx, is not in violation of the of the provisions of Regulation 34 of the SEBI (Delisting of Equity Shares) Regulations, 2021.

Further, we request you to kindly consider our request and take forward our application for reclassification from the present status of Promoter & Promoter Group of the Company to Public Category. EzeRx shall endeavour to provide all necessary information/documents as may be required in respect to reclassification.

In light of the above, the EzeRX requests the Board of Directors of Mankind to consider and take necessary steps to reclassify the EzeRx to "Public" category from "Promoter Group" category in shareholding pattern.

Thanking You,

Yours faithfully  
For EzeRx Health Tech Private Limited

*Chaitali Ray*

Chaitali Roy  
Director

